Ophthalmology

Overview

Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition affecting the eyes and surrounding tissues. Often linked to thyroid disorders like Graves' disease, TED occurs when the immune system mistakenly attacks the orbital region, causing inflammation, swelling, and sometimes damage to eye muscles and the optic nerve. Early diagnosis and targeted infusion therapy can manage disease progression and significantly alleviate symptoms.

Symptoms

• Eye bulging (proptosis) — caused by tissue swelling behind the eyes
• Dry or gritty eye sensation, worsened by light or wind
• Redness and swelling of the eyelids
• Pain or pressure when moving the eyes
• Incomplete eyelid closure leading to dryness and irritation
• Blurred or double vision
• Light sensitivity (photophobia)
• In severe cases: vision loss

When to See a Doctor

Seek medical advice if you notice eye bulging or changes in eye appearance, persistent dry or gritty eyes, swelling or pain around the eyes, or blurred or double vision. Seek urgent care for sudden vision changes, intense pain behind the eyes, or vision loss.

Causes

TED arises when the immune system targets soft tissues around the eyes. It is strongly associated with thyroid dysfunction — especially Graves' disease. Immune antibodies stimulate both thyroid tissue and orbital structures, triggering inflammation. Genetics, smoking, hormonal changes, and other autoimmune conditions may also contribute.

Risk Factors

• Thyroid dysfunction — especially hyperthyroidism or Graves' disease
• Smoking (increases both incidence and severity)
• Female sex — more commonly affected than males
• Age 30–50
• Family history of thyroid disease
• Prior head or neck radiation

Complications

• Vision impairment or loss
• Corneal damage from eyelid exposure
• Misaligned eye muscles causing persistent double vision
• Psychological distress from appearance changes or visual limitations

Treatment Considerations

Targeted biologic infusion therapy has transformed TED treatment, offering a disease-specific approach that reduces orbital inflammation without the broad side effects of systemic corticosteroids. Early treatment is critical to prevent irreversible damage to vision and eye structures. Careful monitoring ensures the best outcomes for each patient.